Arrowhead Pharmaceuticals Inc (ARWR) Common Stock USD0.001

Sell:$77.89Buy:$77.90Price decreased$0.67 (0.85%)

NASDAQ:Price increased1.20%
Market closed |
Prices delayed by at least 15 minutes
Sell:$77.89
Buy:$77.90
Change:Price decreased$0.67 (0.85%)
Deal now
Market closed |
Prices delayed by at least 15 minutes
Sell:$77.89
Buy:$77.90
Change:Price decreased$0.67 (0.85%)
Market closed |
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.

Key people

Christopher Richard Anzalone
Chairman of the Board, President, Chief Executive Officer
Daniel Apel
Chief Financial Officer
Patrick C. O'Brien
Chief Operating Officer, Company Secretary
James Hamilton
Senior Vice President - Discovery and Translational Medicine
William D. Waddill
Lead Independent Director
Mauro Ferrari
Independent Director
Hongbo B. Lu
Independent Director
Adeoye Y. Olukotun
Independent Director
Michael S. Perry
Independent Director
Click to see more

Key facts

  • Shares in issue
    143.52m
  • EPIC
    ARWR
  • ISIN
    US04280A1007
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $10.95bn
  • Employees
    711
  • Exchange
    NASDAQ
  • Index
    S&P 400 Mid Cap, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.